Amgen Inc. buy melinda
Start price
31.08.17
/
50%
€176.34
Target price
12.09.17
€190.00
Performance (%)
7.96%
End price
12.09.17
€190.38
Summary
This prediction ended on 12.09.17 with a price of €190.38. The BUY prediction by melinda finished with a performance of 7.96%. melinda has a follow-up prediction for Amgen Inc. where he still thinks Amgen Inc. is a Buy. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Amgen Inc. | 1.146% | 1.146% | 7.995% | 37.548% |
| iShares Core DAX® | -1.665% | -10.870% | -0.717% | 41.869% |
| iShares Nasdaq 100 | -3.766% | -5.147% | 13.412% | 70.295% |
| iShares Nikkei 225® | -2.803% | -11.299% | 25.461% | 45.956% |
| iShares S&P 500 | -2.299% | -4.801% | 8.938% | 54.178% |
Comments by melinda for this prediction
In the thread Amgen Inc. diskutieren
$
Wenn in Phase III getestet Kopf an Kopf, das Bestreben, reduziert KYPROLIS und Dexamethason das Sterberisiko um 21% und erhöhte die Überlebenszeit von 7,6 Monaten im Vergleich zu Velcade und Dexamethason in Patienten mit rezidivierendem oder refraktärem multiplem Myelom